MapLight’s $372.5M Series D Fuels Momentum in Schizophrenia and Alzheimer’s Psychosis Programs

Redwood City, CA, July 28, 2025 (PRNewswire) -- MapLight Therapeutics raised $372.5 million in an oversubscribed Series D round to advance its lead muscarinic agonist therapy, ML-007C-MA, through Phase 2 trials for schizophrenia and Alzheimer’s-related psychosis. The financing, backed by major new and returning investors, signals strong confidence in the company’s scientific approach and leadership. With this momentum, MapLight aims to expand its CNS pipeline and explore new indications.

Read full article here.